Alphatec Holdings, Inc. $ATEC Holdings Lessened by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC lessened its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 15.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 569,046 shares of the medical technology company’s stock after selling 107,776 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Alphatec were worth $5,873,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of America Corp DE grew its stake in Alphatec by 26.9% during the first quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock valued at $27,863,000 after acquiring an additional 543,059 shares in the last quarter. Emerald Advisers LLC grew its position in shares of Alphatec by 10.4% during the first quarter. Emerald Advisers LLC now owns 1,807,307 shares of the medical technology company’s stock valued at $19,664,000 after purchasing an additional 169,578 shares in the last quarter. Granite Investment Partners LLC grew its position in shares of Alphatec by 4.7% during the first quarter. Granite Investment Partners LLC now owns 1,195,156 shares of the medical technology company’s stock valued at $13,003,000 after purchasing an additional 54,043 shares in the last quarter. Emerald Mutual Fund Advisers Trust grew its position in shares of Alphatec by 27.1% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 1,156,826 shares of the medical technology company’s stock valued at $12,586,000 after purchasing an additional 246,773 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Alphatec by 21.3% during the first quarter. Renaissance Technologies LLC now owns 1,055,100 shares of the medical technology company’s stock valued at $11,479,000 after buying an additional 184,969 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Stock Performance

NASDAQ:ATEC opened at $11.45 on Thursday. The stock’s fifty day moving average is $10.15 and its 200 day moving average is $10.73. Alphatec Holdings, Inc. has a fifty-two week low of $6.82 and a fifty-two week high of $23.29. The firm has a market capitalization of $1.77 billion, a PE ratio of -16.13 and a beta of 0.78.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Tuesday, August 4th. The medical technology company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.07. The company had revenue of $213.51 million during the quarter, compared to the consensus estimate of $211.26 million. Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 13.49%. Alphatec’s revenue was up 15.1% on a year-over-year basis. During the same period last year, the company earned $0.02 earnings per share. Equities analysts forecast that Alphatec Holdings, Inc. will post -0.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Alphatec in a report on Monday, August 3rd. TD Cowen upped their price objective on Alphatec from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. BMO Capital Markets increased their target price on Alphatec from $11.00 to $12.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. UBS Group increased their target price on Alphatec from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Stifel Nicolaus cut their target price on shares of Alphatec from $16.00 to $13.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.40.

Insider Buying and Selling at Alphatec

In related news, General Counsel Tyson Marshall sold 8,168 shares of Alphatec stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total transaction of $78,821.20. Following the completion of the transaction, the general counsel directly owned 630,398 shares of the company’s stock, valued at approximately $6,083,340.70. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Patrick Miles purchased 115,000 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were purchased at an average price of $8.81 per share, for a total transaction of $1,013,150.00. Following the completion of the acquisition, the chief executive officer directly owned 5,893,551 shares in the company, valued at $51,922,184.31. The trade was a 1.99% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 13.48% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.